epitalon comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Often abbreviated AEDG in research literature |
| Common synonyms | Epithalon, epitalon, AEDG | Spelling variants refer to the same tetrapeptide |
| Molecular formula | C14H22N4O9 | Theoretical monoisotopic mass near 390.35 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Freely soluble in water | Hydrophilic peptide; dissolves in aqueous buffer |
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Documentation accompanying research peptides usually includes a certificate of analysis listing the batch number, purity figure, and test methods applied. Buyers comparing suppliers should check whether the reported purity refers to chromatographic area or to a mass-balance calculation, because the two are not equivalent. Counter-ion content, residual solvents, and water content are sometimes omitted from such certificates even though they affect the actual peptide mass present. Independent verification through a second laboratory is the most direct way to confirm that a supplied material matches its label.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Analytical solution methods for non-adhesive contact problem can be classified into two types based on the geometry of the area of contact. A conforming contact is one in which the two bodies touch at multiple points before any deformation takes place (i.e., they just "fit together"). A non-conforming contact is one in which the shapes of the bodies are dissimilar enough that, under zero load, they only touch at a point (or possibly along a line). In the non-conforming case, the contact area is small compared to the sizes of the objects and the stresses are highly concentrated in this area. Such a contact is called concentrated, otherwise it is called diversified. A common approach in linear elasticity is to superpose a number of solutions each of which corresponds to a point load acting over the area of contact. For example, in the case of loading of a half-plane, the Flamant solution is often used as a starting point and then generalized to various shapes of the area of contact. The force and moment balances between the two bodies in contact act as additional constraints to the solution.
Dried spirulina is 5% water, 24% carbohydrates, 8% fat, and 57% protein (table). In a reference amount of 100 g (3.5 oz), dried spirulina powder supplies 290 kilocalories (1,200 kJ) and is a rich source (20% or more of the Daily Value, DV) of numerous essential nutrients, particularly B vitamins (thiamin, riboflavin, and niacin), and dietary minerals, such as iron and manganese (table). The lipid content of spirulina is about 8% by weight. The polyunsaturated fatty acids include gamma-linolenic acid and linoleic acid. In contrast to the "high" content reported in a 2003 study, two other analyses found low levels of omega-3 fatty acids in spirulina.
The first injector pen, branded "Penject", was introduced in 1983 to administer insulin products, following trials begun in 1981 at Southern General Hospital, Scotland, initiated by Sheila Reith who has conceived the device, and funded by Diabetes UK. The invention was announced, and the preliminary trial described, in a January 1981 paper in The Lancet. The patent rights were later sold to Novo Nordisk by Greater Glasgow Health Board. After their introduction, insulin pens had a slow adoption in the United States, with only 2% of insulin being injected via pen in 1999. A major barrier to adoption in the United States was the increased up-front cost of insulin pens compared to traditional injections. Pen adoption in the United States accelerated after studies showed that the higher up-front cost of insulin pens was offset by the increase in compliance, which decreased overall healthcare costs. Historically, pen needles were manufactured in lengths up to 12.7mm. Over time, pen needles designed for insulin pens have become shorter, and a 4mm long needle is considered sufficient for most people to administer subcutaneously correctly. In 1989, an injector pen form of human growth hormone was licensed in New Zealand.
Noted for his longevity in the game, Fletcher played a total of 400 senior VFL/AFL games, which stands as the fifth-highest number of games by any player as of 2023. His AFL career length of 22 years and 58 days is an all-time league record (edging out Vic Cumberland, whose former record was five days shy of 22 years). Fletcher played his 400th game in Round 9, 2015, becoming the third player in VFL/AFL history to reach the milestone (after Michael Tuck and Kevin Bartlett); it would end up being his final game, as he was unable to recover from a groin injury sustained during the match. He holds the outright Essendon games record, having overtaken the previous record of 378 games held by Simon Madden in Round 1, 2014. He is the second-oldest player to play a VFL/AFL game, aged 40 years and 23 days at the time of his final game, behind only the aforementioned Vic Cumberland (who played the 1920 season at the age of 43). With his father, Ken, the Fletchers hold the record for the most VFL/AFL career games played by a father and son, with 664 games between them. On 12 January 2016, during the summer after his retirement, Fletcher was named as one of 34 past and present Essendon players found guilty over their use of illegal supplements during the 2012 AFL season. As a result, Fletcher was suspended from playing at all levels for 24 months, which with backdating and provisional suspension served resulted in suspension until November 2016. However, Fletcher had already retired the previous year, so the suspension was moot.
The data are obtained within 1–2 h and include unique quality control measures through the GFP signal. DSF-GTP has been applied for the characterization of proteins and the screening of small compounds.
Sources: en.wikipedia.org
Gas-sampling sources include flame (atom source), inductively-coupled plasma (atom and ion source), microwave plasma (atom and ion source), direct-current plasma (atom and ion source), and glow discharge (atom and ion source).
With the tearing down of the Berlin Wall and with East and West Germany pursuing re-unification, the Iron Curtain between the West and Soviet-occupied regions came down. By 1989, the Soviet alliance system was on the brink of collapse, and, deprived of Soviet military support, the communist leaders of the Warsaw Pact states were losing power. Grassroots organizations, such as Poland's Solidarity movement, rapidly gained ground with strong popular bases.
=== Alternative protein sources === With the global population expected to reach 9.7 billion by 2050, there is an urgent need for alternative protein sources that are sustainable, nutritious, and environmentally friendly. Plant-based proteins are gaining popularity as they require fewer resources and produce fewer greenhouse gas emissions compared to animal-based proteins. Companies like Beyond Meat and Impossible Foods have developed plant-based meat alternatives that mimic the taste and texture of traditional meat products.
Harmine is a naturally occurring harmala alkaloid with monoamine oxidase-inhibiting under preliminary research for potential anti-HIV properties. It is found in various plants such as Peganum harmala and B. caapi, historically studied for Parkinson's disease and currently in early-phase clinical trials. Harmine is the primary β-carboline alkaloid in ayahuasca and has been studied for potential therapeutic effects including modulation of astrocytic function, anti-inflammatory properties, influence on neural progenitor proliferation, and possible roles in addiction and depression treatment through mechanisms involving glutamate regulation and BDNF signaling.
Sources: en.wikipedia.org
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.
No. Epithalamin is a peptide-rich extract prepared from bovine pineal glands, while epitalon is a short synthetic peptide designed as a defined analogue of it. The synthetic version was intended to provide a reproducible molecule with some of the same proposed biological activity.
Telomere elongation and telomerase activation have been reported in cultured human somatic cells, but evidence from living human subjects is limited and has not been independently confirmed at scale. Reported findings come largely from small studies with differing designs, so the question remains open rather than settled.
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.